drugset / Trial / NCT01449630
A Study of LY3031207 in Healthy Subjects
RandomizedCrossoverDouble-blindBasic science
Summary
This is a phase I study of LY3031207 in healthy subjects. The purposes of this study are to look at safety, how well the study drug is tolerated, and how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Subjects will participate in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.
Timeline
- Start
- 2011-10-24
- Primary completion
- 2012-04-02
- Completion
- 2012-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | LY3031207 | Small molecule | 5 mg | Oral |
| Subject | LY3031207 | Small molecule | 25 mg | Oral |
| Subject | LY3031207 | Small molecule | 75 mg | Oral |
| Subject | LY3031207 | Small molecule | 225 mg | Oral |
| Subject | LY3031207 | Small molecule | 450 mg | Oral |
| Subject | LY3031207 | Small molecule | 900 mg | Oral |
Indications
No indication recorded.